How can the cell & gene therapy sector thrive in the UK?

2 May 2022
uk_london_large

An Expert View from Neelam Patel, chief executive of MedCity, a not-for-profit that serves as the life sciences cluster organization for London.

A year of record global investment into cell and gene therapies, up 16% on 2020’s record £15 billion ($19.5 billion), and an unprecedented number of treatment approvals, affirms that this once-niche field is now a growing part of the biopharma industry.

But, while this is positive news for the UK’s burgeoning life sciences sector, one consequence is rocketing demand for internal and external manufacturing capacity of advanced therapy medicinal products (ATMPs). In the UK, the Cell and Gene Therapy Catapult GMP Manufacturing Report identified year-on-year growth within cell and gene therapy manufacturing throughout 2021, with manufacturing space increasing by 25% from 2020. Meanwhile, the UK’s new  Life Sciences Innovative Manufacturing Fund (LSIMF) pledges £60 million in support to commercial-scale and manufacturing investments by companies at the leading-edge of innovation, including cell and gene therapies (CGTs).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology